Clinical-stage biopharmaceutical company Nuvalent, Inc. (Nasdaq:NUVL) announced on Monday the initiation of HEROEX-1, a Phase 1a/1b clinical trial for NVL-330.
NVL-330 is a novel HER2-selective inhibitor targeting HER2-altered non-small cell lung cancer (NSCLC) in pre-treated patients. HER2 alterations, including exon 20 mutations, are key oncogenic drivers in NSCLC with no approved TKIs for this patient population. NVL-330 aims to address this by maintaining activity against HER2 exon 20 mutations, limiting EGFR-related toxicities, and penetrating the brain to tackle metastases.
HEROEX-1 will evaluate NVL-330's safety, tolerability, recommended Phase 2 dose, pharmacokinetic profile and preliminary anti-tumor activity.
This trial involves a multicenter, open-label, dose-escalation and expansion study design. NVL-330's differentiated preclinical profile supports its potential efficacy in this clinical investigation.
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Anixa Biosciences administers second dose of CAR-T therapy to individual patient
RevOpsis Therapeutics receives SBIR grant of over USD1.8m
AtomVie Global Radiopharma partners with Radiopharm Ventures
Lipella granted patent for innovative drug delivery technology
Adocia patents stable hormone combinations for obesity and diabetes
Accord BioPharma's IMULDOSA receives US FDA approval to treat chronic inflammatory conditions
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA
Quest Diagnostics acquires OhioHealth lab assets
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
GSK reports positive Phase III results for depemokimab in chronic rhinosinusitis with nasal polyps
SkylineDx reveals new data from the MERLIN_001 prospective US multi-centre trial